Compare Merck & Co., Inc. (MRK) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Cloudflare Inc — how do they compare? Merck & Co., Inc. trades at $142.39 (market cap $352.29B), while Cloudflare Inc trades at $343.25 (market cap $122.12B). The key difference: Merck & Co., Inc. is far larger — about 2.9× Cloudflare Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Cloudflare Inc for 61 Days on average.
| MRK | NET | |
|---|---|---|
Market Cap | $352.29B | $122.12B |
Volume | 6,348,796 | 2,321,930 |
Sector | Health | Technology |
52-Week High | $156.43 | $359.60 |
52-Week Low | $82.49 | $160.16 |
Typical Hold Time | 98 Days | 61 Days |
Enterprise Value | $399.05B | $121.49B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Cloudflare (NET) trades at $341.70, down 3.75% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue growth is strong, reaching $2.17 billion in 2025, but the company remains unprofitable with a net income margin of -8.21%. Recent news highlights product launches like Cloudflare Basin and partnerships, such as with Deutsche Telekom, driving positive sentiment. The stock is near its 52-week high, reflecting investor optimism around its AI and security offerings.
Outlook is mixed: robust revenue growth and analyst bullishness (70.7% buy ratings) support upside, but high valuations (P/S of 48.03) and persistent losses pose risks. Investors should weigh growth potential against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
